The Reversion of DNA Methylation at Coronary Heart Disease Risk Loci in Response to Prevention Therapy

Coronary heart disease (CHD) is preventable, but the methods for assessing risk and monitoring response rely on imprecise lipid-based assessments. Recently, we have shown that an integrated genetic–epigenetic test includes three methylation-sensitive digital PCR assays predicts 3-year incident CHD better than methods. However, whether methylation sites change in to therapies alter not known. Therefore, assessed at these CHD-related DNA from 39 subjects before after months of biochemically verified smoking cessation, then analyzed relationship between each intensity as by cg05575921 methylation. We found that, those who quit smoking, one marker (cg00300879) was significantly associated with (p < 0.04). conclude changes occur within cessation a major factor CHD. This suggests effectiveness treatment other factors, such high cholesterol, may be similarly quantifiable using epigenetic approaches. Further studies determine status factors are indicated.